U.S. markets open in 8 hours 47 minutes

Fresenius Medical Care AG & Co. KGaA (FMCQF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
45.920.00 (0.00%)
At close: 10:41AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close45.92
BidN/A x N/A
AskN/A x N/A
Day's Range45.92 - 45.92
52 Week Range45.92 - 79.91
Avg. Volume5,951
Market Cap13.474B
Beta (5Y Monthly)0.90
PE Ratio (TTM)16.46
Earnings DateN/A
Forward Dividend & Yield1.41 (3.07%)
Ex-Dividend DateMay 13, 2022
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for FMCQF

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverThis edition features the changing winds of solar energy, the wide moats in network security, our pondering Zendesk's recent acquisition, and Fresenius, Deliveroo, and New World Development.
    Fair Value
    Economic Moat
    7 months agoMorningstar
View more
  • PR Newswire

    CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

    Fresenius Medical Care (NYSE: FMS; Frankfurt Stock Exchange: FME) and CytoSorbents Corporation (NASDAQ: CTSO) have expanded their partnership by establishing a multi-stage global collaboration to combat life-threatening diseases in critical care for an initial term of three years. The new agreement provides for the combined marketing and promotion of CytoSorb® with Fresenius Medical Care's critical care products by Fresenius Medical Care's marketing organization worldwide, excluding the United S

  • PR Newswire

    Fresenius Medical Care North America Introduces First Single-Use Integrated Bloodline to Support Fluid Management in Dialysis

    Fresenius Medical Care North America's (FMCNA) Renal Therapies Group today announced the availability of the CombiSet SMARTECHTM, the first available single-use bloodline with an integrated Crit-Line® blood chamber (CLiC™) that simplifies use by reducing the number of manual connections required. The CLICTM Blood Chamber is built into the bloodline itself and is designed to provide optimal performance with the 2008® series hemodialysis machines.

  • Business Wire

    Fresenius Medical Care Celebrates Diversity and Unity of a Global Nurse Workforce

    HONG KONG, May 12, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care’ campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America.